High Th1/Th2 Ratio in Patients with Multiple Myeloma

Overview

Journal Leuk Res

Date 2004 Dec 21

PMID 15607360

Citations 35

Authors

Hatsue Ogawara

Hiroshi Handa

Tohru Yamazaki

Takuma Toda

Kensuke Yoshida

Natsumi Nishimoto

Wedad Hamdi Saleh Al-maQuol

Yoriaki Kaneko

Takafumi Matsushima

Norifumi Tsukamoto

Yoshihisa Nojima

Morio Matsumoto

Morio Sawamura

Hirokazu Murakami

Affiliations

Soon will be listed here.

Abstract

To determine the clinical significance of the T helper 1(Th1)/T helper 2 (Th2) ratio in multiple myeloma, the intracellular IFN-gamma and IL-4 were analyzed by flow cytometry in 56 patients with multiple myeloma. The mean Th1/Th2 ratio of cases in the initial diagnosis phase and the refractory phase were higher than that of the control group. The mean serum beta-2-microglobulin in the high Th1/Th2 subgroup was significantly higher than that in the normal Th1/Th2 subgroup (P < 0.05). In conclusion, the Th1/Th2 ratio was closely related to the disease status of multiple myeloma.

Citing Articles

Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma.

Gonzalez-Montes Y, Rodriguez-Romanos R, Villavicencio A, Osca-Gelis G, Gonzalez-Bartulos M, Llopis F Front Immunol. 2023; 14:1158105.

PMID: 37122695 PMC: 10143497. DOI: 10.3389/fimmu.2023.1158105.

A Journey through the Inter-Cellular Interactions in the Bone Marrow in Multiple Myeloma: Implications for the Next Generation of Treatments.

Hervas-Salcedo R, Martin-Antonio B Cancers (Basel). 2022; 14(15).

PMID: 35954459 PMC: 9367481. DOI: 10.3390/cancers14153796.

Development of a Risk Assessment Model for Early Grade ≥ 3 Infection During the First 3 Months in Patients Newly Diagnosed With Multiple Myeloma Based on a Multicenter, Real-World Analysis in China.

Shang Y, Wang W, Liang Y, Kaweme N, Wang Q, Liu M Front Oncol. 2022; 12:772015.

PMID: 35372017 PMC: 8967980. DOI: 10.3389/fonc.2022.772015.

Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma.

Swamydas M, Murphy E, Ignatz-Hoover J, Malek E, Driscoll J J Hematol Oncol. 2022; 15(1):17.

PMID: 35172851 PMC: 8848665. DOI: 10.1186/s13045-022-01234-2.

Involvement of Alarmins in the Pathogenesis and Progression of Multiple Myeloma.

Murdaca G, Allegra A, Paladin F, Calapai F, Musolino C, Gangemi S Int J Mol Sci. 2021; 22(16).

PMID: 34445745 PMC: 8396675. DOI: 10.3390/ijms22169039.